The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Charles Schwab Corp. (SCHW), ...
DelveInsight's Advanced Therapy Medicinal Products Market Insights report provides the current and forecast market analysis, ...
9h
Hosted on MSNGilead’s lenacapavir applications for HIV gain EMA validationGilead Sciences has announced the European Medicines Agency’s (EMA) validation for a parallel accelerated review of ...
Three bovine veterinarians had undetected H5N1 avian influenza infections despite no apparent contact with infected cows, ...
Investing.com -- Morgan Stanley expects the FDA to approve Gilead Sciences (NASDAQ: GILD )' Lenacapavir (LEN) for HIV ...
Salesforce is expected to report fourth-quarter results after the market closes Wednesday, with analysts largely bullish on the cloud-based software company's stock, anticipating AI-driven gains.
The discussion ended with a bold call to action for businesses, healthcare providers, and policymakers: health equity must be a priority—not just ethically, but economically. As Burgess put it: “This ...
The EMA is set to perform accelerated reviews of Gilead Sciences’ applications for its twice-yearly injectable for HIV ...
We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...
Biotech companies saw the most notable insider purchases of the past week. A Mexican billionaire also continued to build a ...
Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) saw some unusual options trading activity on Thursday. Stock investors bought 16,698 call options on the stock. This represents an increase of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results